Objective:To observe the clinical efficacy of azithromycin for the treatment of Mycoplasma pneumoniae pneumonia(MPP)with gene mutations at site A2063G of 23S rRNA in children.Methods:Data were retrospectively collected for 242 children diagnosed with MPP at Sichuan Provincial Maternity and Child Health Care Hospital from January to December 2023,in whom MPP was detected using targeted next-generation sequencing(tNGS).According to the presence or absence of mutations,the children were classified into mutation group(88 cases)and non-mutation group(154 cases).Results:Gene mutations at site A2063G of 23S rRNA were detected in 88 patients.The chest X-rays of both groups showed more lesions in the right lung than in the left lung.Both groups were treated with azithromycin and compared for differences in age,sex,duration of fever,C-reactive protein level,time to improvement of chest X-rays,days of medication,and response rate,with no significant differences found in the above indicators(P>0.05).However,the duration of respiratory symptoms was significantly longer in the mutation group than in the non-mutation group[(11.51±3.31)d vs.(10.06±3.63)d,P<0.05].Conclusion:Azithromycin is effective in treating MPP with gene mutations at site A2063G of 23S rRNA.

Objective:This study aimed to evaluate the immunoprotective effect of anti-rabies virus cocktail monoclonal antibody Zamerovimab/Mazorelvimab after rabies exposure.Methods:The dynamic data of rabies virus neutralizing antibody (RVNA) were analyzed in the Zamerovimab/Mazorelvimab Chinese phase Ⅲ study (clinical trial registration number: CTR20201819).Results:The full analysis set showed that RVNA geometric mean titers (GMT) on the 4 th, 8 th, 15 th, 43 rd, and 99 th day in the Zamerovimab/Mazorelvimab group were 4.413 IU/ml, 5.178 IU/ml, 17.062 IU/ml, 14.672 IU/ml, and 2.836 IU/ml, respectively, while those in the human rabies immunoglobulin (HRIG) group were 0.299 IU/ml, 0.451 IU/ml, 11.374 IU/ml, 18.063 IU/ml, and 6.769 IU/ml, respectively. The positive rates of RVNA on the 4 th, 8 th, 15 th, 43 rd, and 99 th day in the Zamerovimab/Mazorelvimab group were 99.9%, 99.6%, 100%, 100%, and 97.4%, respectively, while those in the HRIG group were 23.3%, 34.1%, 97.6%, 99.6%, and 98.4%, respectively. Conclusions:Compared with HRIG, Zamerovimab/Mazorelvimab cocktail monoclonal antibody reached the required protection level of RVNA very soon, thus effectively provided an immediate neutralizing effect of passive immunization therapies against rabies virus.

Objective To explore the role of p38MAPK and TGF?2 in the development of diabetic retinopathy.Methods Fifteen Hamsters were induced into diabetic models by intraperitoneal injection of Streptozotocin(40 mg/kg once a day) for 3 d and 13 Hamsters were successfully established,whose blood glucose was over 13.5 mmol/L.Ten Hamsters as controls were intraperitoneally injected of physical saline of the same volume.At 16th week after induction,the total RNA of retina from all sacrificed Hamsters was collected.The mRNA expressions of p38MAPK,TGF?2 in retina were detected by semi-quantitative RT-PCR and their protein levels by Western blotting.Results The mRNA expressions of p38MAPK,TGF?2 in retina were of high tendency and their protein levels increased.Conclusion p38MAPK signal pathway may involve in the pathogenesis of diabetic retinopathy.

Following extensive bowel resection， the intestinal tract undergoes a variety of adaptive responses to enhance bowel function． The purpose of this study was to determine the effect of glutamine-supplemented parenteral nutrition on mucosal cellularity and gut function． In addition， enterocyte gene expression of two relevant systems was also characterized and related to the structural and functional changes that occurred．Male Wistar rats underwent a 60％ small bowel resection and jugular vein catheterization and were randomized into two groups． The control group （n＝10） received a standard intravenous nutritional solution and the study group （n＝10） received a similar solution but enriched with alanylglutamine dipeptide． After 7 days blood was taken for amino acid analysis， and bowel was harvested to determine mucosal morphology and expression of mucosal cell glutaminase and IGF-I mRNA． Mesentery lymphnodes were cultured to determine the presence of bacteria and thus access bacteria translocation． Serum glutamine concentration and mucosal architecture were maintained in the study group compared to the controls． Seventy percent of lymphnodes were cultured positive in control vs． only 20％ in the study group （P＜0．05）． Jejunal mucosal glutaminase and ileum mucosal IGF-I mRNA increased twofold and threefold respectively compared to control animals．Parenteral nutrition supplemented with alanyl-glutamine dipeptide supports mucosal cellularity and regional immune function in rodents following intestinal resection， These alterations are associated with enhanced enterocyte expression of glutaminase and IGF-I． These changes may facilitate the structural and functional alterations which were observed in the glutamine treated animals．